Novartis to sell 70.68% stake in Novartis India for 14.46 billion rupees
Novartis agreed to sell its 70.68% stake in Novartis India Ltd. for 14.46 billion rupees. The buyers also launched a 26% open offer at 860.84 rupees per share.
Voveran
DrugAlso known as: Voveran
Drug Profile
Voveran is a diclofenac-based NSAID brand marketed in India in multiple formulations (including gastro-resistant and sustained-release oral forms and topical gel). Labeling describes its use across inflammatory and painful musculoskeletal and related conditions. It is a marketed prescription product line rather than an investigational drug.
- Drug Class
- Non-steroidal anti-inflammatory drug (NSAID; diclofenac)
- Approval Status
- Marketed prescription product in India
- Mechanism of Action
- Diclofenac acts via prostaglandin synthetase inhibition (NSAID pharmacology)
- Voveran
- \Voveran SR\
- \Voveran Maxxgel\
- \Inflammatory and degenerative rheumatic conditions (including rheumatoid arthritis, ankylosing spondylitis, osteoarthritis, spondylarthritis)\
- \Post-traumatic and post-operative pain, inflammation and swelling\
- \Primary dysmenorrhoea and other inflammatory gynaecologic conditions\
Related News
Novartis Exits Indian Listed Unit With $159 Million Stake Sale
Novartis AG sells its entire 70.68% stake in Novartis India Ltd. for $159 million to a consortium of investors, concluding a two-year strategic review while maintaining operations through its wholly-owned Indian subsidiary.
Novartis AG Sells 70.68% Stake in India Unit to ChrysCapital for Rs 1,446 Crore
Swiss pharmaceutical major Novartis AG has signed a definitive agreement to sell its entire 70.68% stake in Novartis India to a ChrysCapital-led consortium for Rs 1,446 crore, with a mandatory open offer for an additional 26% from public shareholders.
Novartis AG Sells 70.68% Stake in India Unit for ₹1,446 Crore to PE Consortium
Novartis AG agreed to sell its entire 70.68% stake in Novartis India to a consortium led by WaveRise Investments, ChrysCapital, and Two Infinity Partners for approximately ₹1,446 crore, triggering a mandatory open offer at ₹860.64 per share.
Novartis to Exit Indian Unit With $159 Million Stake Sale to PE Consortium
Swiss drugmaker Novartis will sell its entire 70.68% stake in its listed Indian unit to a private equity consortium for $159 million as part of broader global restructuring. Shares of Novartis India surged nearly 20% following the announcement.